SP Enanthate Forte

SP ENANTHATE FORTE FROM SP LABORATORY
COMPOSITION OF THE MEDICINAL PRODUCT
1 ml of solution contains:
- active substance: testosterone enanthate 500 mg;
- auxiliary substances: benzyl alcohol, peach, or peanut oil.

DESCRIPTION OF THE MEDICINAL PRODUCT
SP Enanthate Forte- for intramuscular injection, contains testosterone enanthate which is insoluble in water.
Androgens are derivatives of cyclopentane-perhydrophenanthrene. Endogenous androgens are C-17 side-chain C-19 steroids with two angular methyl groups. Testosterone is the major endogenous androgen. In its active form, SP Enanthate Forte has a 17-beta-hydroxy group.
Esterification of the 17-beta-hydroxy group produces compounds (testosterone propionate and testosterone enanthate) that have a longer duration of action.
Testosterone enanthate is an ester of testosterone. Testosterone is the primary androgen hormone synthesized and released by the testicles. It is responsible for the growth and development of the male sexual organs and secondary sexual characteristics (maturation of the prostate, seminal vesicles, penis, and scrotum), distribution of male hair (face, pubis, chest), development of body muscles, and distribution of fat. Retains sodium, nitrogen, potassium, and phosphorus increases anabolism and reduces protein catabolism. A premature increase in plasma testosterone levels during the prepubertal period causes the epiphyses to close and the growth to stop. Stimulates the production of erythropoietin and erythrocytes. Through the feedback mechanism, it inhibits the secretion of luteinizing and folliculostimulatory pituitary hormones and causes the suppression of spermatogenesis.
In women, it inhibits pituitary gonadotrophic function, ovarian function, mammary glands, endometrial atrophy.

Due to its antagonistic action against estrogen, it is used in the treatment of uterine fibroids, endometriosis, breast cancer.

Testosterone enanthate is slowly absorbed.

Peak plasma concentrations are reached more than 72 hours after intramuscular administration.

Duration of action: 2-4 weeks.
Half time: 15-16 days
Routes of administration: intramuscular injection
Recommended dose for men: 500-1000 mg / 7 days;
Women: Not recommended
Acne: Yes
Water retention: yes
Hypertension: yes
Hepatotoxicity: no
Aromatase: yes (high, 100% testosterone)
Progestogenic activity: low
DHT (dihydrotestosterone) conversion: no
Decreased HPTA function (own testosterone production): yes
Anabolic activity: 100%
Androgenic activity: 100%
Detection time: 3 months after the last injection.

THERAPEUTIC INDICATIONS
In men - hormone replacement therapy for testosterone deficiency disorders:
- retention of sexual maturity;
- eunuchoidism, non-development of the genitals;
- hypopituitarism;
- symptoms of male climax (decreased libido and physical and intellectual activity);
- post-castration syndrome (androgen deficiency after castration);

For women:
- hyperestrogenemia, functional hemorrhages;
- uterine fibroids;
- endometriosis;
- menopause (in combination with estrogen);
- breast cancer;

DOSAGE AND METHOD OF ADMINISTRATION
Deep intramuscular. The dose is determined individually according to disease, sex, age, clinical efficacy. Adults are usually given 50-200 mg intramuscularly every 2-4 weeks. It is not recommended to exceed 400 mg per month. The duration of treatment is determined individually.

In hypogonadism in men such as eunuchism, the recommended doses are 50-400 mg every 2-4 weeks.

If sexual maturity is retained, 50-200 mg is administered every 2-4 weeks for 4-6 months.

In inoperable breast cancer in women: 200-400 mg every 2-4 weeks.

For bodybuilding purposes, the average dosage for men is 500-1000 mg per week, women 50-100 mg. The cycle lasts from 8 to 16 weeks.

- Priapism and other symptoms of sexual hyperstimulation (frequent erection);
- altered spermatogenesis and disorders of sperm maturation, oligospermia, and decreased ejaculate volume;
- in women - bleeding from the genitals, increased libido; symptoms of virilization are possible with prolonged administration;
- hirsutism, gynecomastia;
- seborrhea, acne, oily skin, hair loss;
- sodium and water retention, edema;
- symptoms of hypercalcemia;
- nausea, cholestatic jaundice, increased levels of liver transaminases (normalize when stopping treatment);
- headache, depression, aggression, anxiety, sleep disorders, paresthesias.
Pain at the injection site is possible.

 Common side effects are:
 nausea, water retention, high blood pressure, painful erections, vomiting, bitter taste in the mouth; change in sexual appetite, fatigue, irritation of the mouth, tenderness or swelling of the gums, headache, and aggressive behavior.
SP Enanthate Forte contains endogenous androgens, which are responsible for the normal growth and development of the male sexual organs and for maintaining secondary sexual characteristics. These effects include enlargement and maturation of the prostate, seminal vesicles, penis, and scrotum; developing the distribution of male hair, such as beard, pubic hair, chest, and axillary hair; enlargement of the larynx, thickening of the vocal cords, changes in body muscles and distribution of fat.
SP Enanthate Forte causes the retention of nitrogen, sodium, potassium, phosphorus, and decreased urinary calcium excretion. Androgens have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance improves only when there is a sufficient intake of calories and protein.
Androgens are responsible for growth in adolescence and for the eventual cessation of linear growth, which is caused by the fusion of epiphyseal growth centers. In children, exogenous androgens accelerate linear growth rates but can cause a disproportionate advance in bone maturation. Long-term use of SP Enanthate Forte may cause the epiphyseal growth center to fuse and the growth process to stop.

During exogenous androgen administration, endogenous testosterone release is inhibited by feedback inhibition of pituitary luteinizing hormone (LH).

CONTRAINDICATIONS
Individual hypersensitivity to the drug, prostate or breast cancer; prostate hyperplasia with symptoms of urinary disorders; nephrosis or the nephrotic phase of nephritis, edema; hypercalcemia; liver function disorders; Diabetes; heart or coronary heart disease, history of myocardial infarction, atherosclerosis in the elderly; pregnancy, lactation.

SPECIAL WARNINGS AND PRECAUTIONS FOR USE
In case of androgen-dependent side effects, it is necessary to stop taking the medicine. After the side effects have disappeared, resume treatment in lower doses.